Diabetic Macular Edema Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Diabetic Macular Edema Market Overview
The Diabetic Macular Edema market size was $5.05 billion in 2021 across the 7MM (seven major pharmaceutical markets). The market is forecast to achieve a CAGR of more than 8% during the forecast period.
Diabetic Macular Edema is a complication of type 1 and 2 diabetes with diabetic retinopathy. It is a leading cause of visual impairment and blindness in first-world countries, affecting over 28 million people (International Diabetes Federation, 2016; de Moura et al., 2020). The DME research report provides an overview of DME – including epidemiology, disease etiology, and management. The report will help to develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
For more insights on this report, download a free report sample
Key Regions in the Diabetic Macular Edema Market
Seven major pharmaceutical markets (7MM) covered in this report are the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan. The US has the largest market share.
Diabetic Macular Edema Market, by Regions
For more regional insights, download a free report sample
DME Market Drivers
An increase in therapies with a longer duration of action, such as Kodiak Science’s KSI-301, means fewer treatment days, consequently improving patient compliance for DME patients who already experience heavy treatment burdens. In addition, the diabetic population is set to grow in line with the increased prevalence of risk factors such as obesity. Such factors will drive market growth in the coming years.
DME Market Barriers
Expensive therapies will face reimbursement challenges in markets where cost-conscious decisions are increasingly implemented. In addition, the inferior efficacy of pipeline agents will continue to leave many patients without adequate suppression of angiogenesis. This may hamper the growth of the market in focus in the coming years.
Classifications in the DME Market
DME is commonly classified as either focal (fDME) or diffuse (dDME). Diagnostic techniques used to diagnose DME subsets include optical coherence tomography (OCT) and fluorescein angiography (FA).
FDME
fDME involves fluid leaking from dilated capillaries and retinal microaneurysms. This is mainly associated with internal damage of BRB and presents as retinal fluid collection only in the outer retina. fDME may further be characterized by the presence of hard exudates.
DDME
DDME, on the other hand, consists of fluid leaking from the entire foveal circumference. This is mainly associated with external damage to the BRB; extensive capillary leakage leads to retinal fluid collection in the inner retina. dDME patients may also be susceptible to cystoid macular edema.
Key Pipeline Products in the DME Market
Diabetic Macular Edema has Ranibizumab, Aflibercept, Bevacizumab, Dexamethasone, Fluocinolone Acetonide, Triamcinolone Acetonide, Ranibizumab Biosimilar, and Nepafenac in the pipeline.
Key Players in the DME Market
Some of the key players in the Diabetic Macular Edema market are Novartis, Bayer, Alcon, Abbvie, and Regeneron.
Market Report Overview
Market size (2021 in 7MM) | $5.05 billion |
CAGR (2021 – 2031) | >8% |
Classifications | FDME and DDME |
Key Products | Ranibizumab, Aflibercept, Bevacizumab, Dexamethasone, Fluocinolone Acetonide, Triamcinolone Acetonide, Ranibizumab Biosimilar, and Nepafenac |
Key players | Novartis, Bayer, Alcon, Abbvie, and Regenron |
Scope
- Overview of DME – including epidemiology, disease etiology and management.
- Topline DME drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
- Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU and Japan over the 10-year forecast period.
- Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global DME therapeutics market. Insightful review of the key industry drivers and barriers.
Key Highlights
DME market will grow significantly during the forecast period, at a CAGR of 8.2%.
Late-stage pipeline therapies are anticipated to drive growth in the DME market.
Reducing treatment burden is an important unmet need for DME.
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global DME therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Diabetic Macular Edema market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global DME therapeutics market from 2021-2031.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Bayer
Roche
Novartis
AbbVie
Samsung Bioepis
Genentech
Outlook Therapeutics
Kodiak Sciences
Allergan
Alimera Sciences
Alcon
Wakamoto Pharmaceutical
Momenta Pharmaceuticals
Mylan NM
Xbrane Biopharma
STADA Arzneimittel AG
Oculis SA
Apexian Pharmaceuticals
Ocuphire Pharma
Bicycle Therapeutics
Oxurion
Table of Contents
Table
Figures
Frequently asked questions
-
What was the DME market size in 2021?
The Diabetic Macular Edema market size was $5.05 billion in 2021 across the 7MM.
-
What is the DME market growth rate?
The Diabetic Macular Edema market is forecast to achieve a CAGR of more than 8% during the forecast period.
-
What are the classifications in the DME market?
The key classifications in the Diabetic Macular Edema market are FDME and DDME.
-
What are the key products in the pipeline in the DME market?
Ranibizumab, Aflibercept, Bevacizumab, Dexamethasone, Fluocinolone Acetonide, Triamcinolone Acetonide, Ranibizumab Biosimilar, and Nepafenac are in the pipeline in DME market.
-
Who are the key players in the DME market?
Some of the key players in the Diabetic Macular Edema market are Novartis, Bayer, Alcon, Abbvie, and Regeneron.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.